|
|
(4 intermediate revisions not shown.) |
Line 1: |
Line 1: |
| + | |
| ==Substrate-binding loop movement with inhibitor PT10 in the tetrameric Mycobacterium tuberculosis enoyl-ACP reductase InhA== | | ==Substrate-binding loop movement with inhibitor PT10 in the tetrameric Mycobacterium tuberculosis enoyl-ACP reductase InhA== |
- | <StructureSection load='4oxy' size='340' side='right' caption='[[4oxy]], [[Resolution|resolution]] 2.35Å' scene=''> | + | <StructureSection load='4oxy' size='340' side='right'caption='[[4oxy]], [[Resolution|resolution]] 2.35Å' scene=''> |
| == Structural highlights == | | == Structural highlights == |
- | <table><tr><td colspan='2'>[[4oxy]] is a 4 chain structure with sequence from [http://en.wikipedia.org/wiki/"bacillus_tuberculosis"_(zopf_1883)_klein_1884 "bacillus tuberculosis" (zopf 1883) klein 1884]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4OXY OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4OXY FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[4oxy]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Mycobacterium_tuberculosis Mycobacterium tuberculosis]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4OXY OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4OXY FirstGlance]. <br> |
- | </td></tr><tr><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=1TN:5-HEXYL-2-(2-NITROPHENOXY)PHENOL'>1TN</scene>, <scene name='pdbligand=NAD:NICOTINAMIDE-ADENINE-DINUCLEOTIDE'>NAD</scene><br> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.3501Å</td></tr> |
- | <tr><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4ohu|4ohu]], [[4oxk|4oxk]], [[4oxn|4oxn]], [[2x23|2x23]], [[2b36|2b36]]</td></tr>
| + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=1TN:5-HEXYL-2-(2-NITROPHENOXY)PHENOL'>1TN</scene>, <scene name='pdbligand=NAD:NICOTINAMIDE-ADENINE-DINUCLEOTIDE'>NAD</scene></td></tr> |
- | <tr><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">MT1531,MTCY277.05,Rv1484,inhA ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=1773 "Bacillus tuberculosis" (Zopf 1883) Klein 1884])</td></tr> | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4oxy FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4oxy OCA], [https://pdbe.org/4oxy PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4oxy RCSB], [https://www.ebi.ac.uk/pdbsum/4oxy PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4oxy ProSAT]</span></td></tr> |
- | <tr><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Enoyl-[acyl-carrier-protein]_reductase_(NADH) Enoyl-[acyl-carrier-protein] reductase (NADH)], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=1.3.1.9 1.3.1.9] </span></td></tr>
| + | </table> |
- | <tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4oxy FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4oxy OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4oxy RCSB], [http://www.ebi.ac.uk/pdbsum/4oxy PDBsum]</span></td></tr> | + | == Function == |
- | <table> | + | [https://www.uniprot.org/uniprot/INHA_MYCTU INHA_MYCTU] |
| <div style="background-color:#fffaf0;"> | | <div style="background-color:#fffaf0;"> |
| == Publication Abstract from PubMed == | | == Publication Abstract from PubMed == |
Line 17: |
Line 18: |
| From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> |
| </div> | | </div> |
| + | <div class="pdbe-citations 4oxy" style="background-color:#fffaf0;"></div> |
| + | |
| + | ==See Also== |
| + | *[[Enoyl-Acyl-Carrier Protein Reductase 3D structures|Enoyl-Acyl-Carrier Protein Reductase 3D structures]] |
| == References == | | == References == |
| <references/> | | <references/> |
| __TOC__ | | __TOC__ |
| </StructureSection> | | </StructureSection> |
- | [[Category: Garcia-Diaz, M.]] | + | [[Category: Large Structures]] |
- | [[Category: Lai, C T.]] | + | [[Category: Mycobacterium tuberculosis]] |
- | [[Category: Li, H J.]] | + | [[Category: Garcia-Diaz M]] |
- | [[Category: Liu, N.]] | + | [[Category: Lai CT]] |
- | [[Category: Pan, P.]] | + | [[Category: Li HJ]] |
- | [[Category: Simmerling, C.]] | + | [[Category: Liu N]] |
- | [[Category: Sullivan, T J.]] | + | [[Category: Pan P]] |
- | [[Category: Tonge, P J.]]
| + | [[Category: Simmerling C]] |
- | [[Category: Bacterial fatty acid biosynthesis]] | + | [[Category: Sullivan TJ]] |
- | [[Category: Conformational heterogeneity]] | + | [[Category: Tonge PJ]] |
- | [[Category: Enzyme-inhibitor complex]] | + | |
- | [[Category: Substrate-binding loop refolding]]
| + | |
| Structural highlights
Function
INHA_MYCTU
Publication Abstract from PubMed
Slow-onset enzyme inhibitors are of great interest for drug discovery programs since the slow dissociation of the inhibitor from the drug-target complex results in sustained target occupancy leading to improved pharmacodynamics. However, the structural basis for slow-onset inhibition is often not fully understood, hindering the development of structure-kinetic relationships and the rational optimization of drug-target residence time. Previously we demonstrated that slow-onset inhibition of the Mycobacterium tuberculosis enoyl-ACP reductase InhA correlated with motions of a substrate-binding loop (SBL) near the active site. In the present work, X-ray crystallography and molecular dynamics simulations have been used to map the structural and energetic changes of the SBL that occur upon enzyme inhibition. Helix-6 within the SBL adopts an open conformation when the inhibitor structure or binding kinetics is substrate-like. In contrast, slow-onset inhibition results in large-scale local refolding in which helix-6 adopts a closed conformation not normally populated during substrate turnover. The open and closed conformations of helix-6 are hypothesized to represent the EI and EI* states on the two-step induced-fit reaction coordinate for enzyme inhibition. These two states were used as the end points for nudged elastic band molecular dynamics simulations resulting in two-dimensional potential energy profiles that reveal the barrier between EI and EI*, thus rationalizing the binding kinetics observed with different inhibitors. Our findings indicate that the structural basis for slow-onset kinetics can be understood once the structures of both EI and EI* have been identified, thus providing a starting point for the rational control of enzyme-inhibitor binding kinetics.
A Structural and Energetic Model for the Slow-Onset Inhibition of the Mycobacterium tuberculosis Enoyl-ACP Reductase InhA.,Li HJ, Lai CT, Pan P, Yu W, Liu N, Bommineni GR, Garcia-Diaz M, Simmerling C, Tonge PJ ACS Chem Biol. 2014 Apr 18;9(4):986-93. doi: 10.1021/cb400896g. Epub 2014 Mar 10. PMID:24527857[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
See Also
References
- ↑ Li HJ, Lai CT, Pan P, Yu W, Liu N, Bommineni GR, Garcia-Diaz M, Simmerling C, Tonge PJ. A Structural and Energetic Model for the Slow-Onset Inhibition of the Mycobacterium tuberculosis Enoyl-ACP Reductase InhA. ACS Chem Biol. 2014 Apr 18;9(4):986-93. doi: 10.1021/cb400896g. Epub 2014 Mar 10. PMID:24527857 doi:http://dx.doi.org/10.1021/cb400896g
|